Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13737314 | 0.77 | KDM4E (0.56) | KDM4EALDH1A1 | |
| SCHEMBL15990725 | 0.77 | KDM4E (0.56) | KDM4EALDH1A1 | |
| SCHEMBL13736733 | 0.77 | KDM4E (0.56) | KDM4EALDH1A1 | |
| SCHEMBL4200838 | 0.76 | MEN1 (0.54) | KDM4E | |
| SCHEMBL389750 | 0.76 | SLC6A3 (0.45) | KDM4EALDH1A1 | |
| SCHEMBL7449557 | 0.76 | CHRNB2 (0.48) | KDM4EALDH1A1 | |
| SCHEMBL29714884 | 0.76 | CHRNB2 (0.48) | KDM4EALDH1A1 | |
| Hydrochloric Acid SCHEMBL26187206 | 0.75 | MEN1 (0.57) | KDM4E | |
| Hydrochloric Acid SCHEMBL29714883 | 0.75 | CHRNB2 (0.47) | KDM4EALDH1A1 | |
| SCHEMBL30856730 | 0.73 | ALDH1A1 (0.47) | KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8101764-B2 | MCH receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| US-20100016350-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY | 2010-01-21 | — | — | US | disclosed |
| EP-2029610-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | Eli Lilly & Company (US) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007146759-A2 | NOVEL MCH RECEPTOR ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2007-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016350-A1 | NOVEL MCH RECEPTOR ANTAGONISTS | MCHR1, MCHR2, MC1R | KDM4E 2661/4885ALDH1A1 1274/4885HRH3 124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.